Cargando…
A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway
BACKGROUND: We have previously demonstrated that ginsenoside compound K can attenuate the formation of atherosclerotic lesions. Therefore, ginsenoside compound K has potential for atherosclerosis therapy. How to improve the druggability and enhance the antiatherosclerotic activity of ginsenoside com...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273626/ https://www.ncbi.nlm.nih.gov/pubmed/37322486 http://dx.doi.org/10.1186/s13020-023-00758-0 |
_version_ | 1785059692836290560 |
---|---|
author | Huang, Yan Ran, Xiaodong Liu, Hongmei Luo, Mingming Qin, Yiyu Yan, Jinqiong Li, Xiaohui Jia, Yi |
author_facet | Huang, Yan Ran, Xiaodong Liu, Hongmei Luo, Mingming Qin, Yiyu Yan, Jinqiong Li, Xiaohui Jia, Yi |
author_sort | Huang, Yan |
collection | PubMed |
description | BACKGROUND: We have previously demonstrated that ginsenoside compound K can attenuate the formation of atherosclerotic lesions. Therefore, ginsenoside compound K has potential for atherosclerosis therapy. How to improve the druggability and enhance the antiatherosclerotic activity of ginsenoside compound K are the core problems in the prevention and treatment of atherosclerosis. CKN is a ginsenoside compound K derivative that was previously reported to have excellent antiatherosclerotic activity in vitro, and we have applied for international patents for it. METHODS: Male C57BL/6 ApoE(−/−) mice were fed a high-fat and high-choline diet to induce atherosclerosis and were subjected to in vivo studies. In vitro, the CCK-8 method was applied to evaluate cytotoxicity in macrophages. Foam cells were utilized, and cellular lipid determination was performed for in vitro studies. The area of atherosclerotic plaque and fatty infiltration of the liver were measured by image analysis. Serum lipid and liver function were determined by a seralyzer. Immunofluorescence and western blot analysis were conducted to explore the alterations in the expression levels of lipid efflux-related proteins. Molecular docking, reporter gene experiments and cellular thermal shift assays were used to verify the interaction between CKN and LXRα. RESULTS: After confirming the therapeutic effects of CKN, molecular docking, reporter gene experiments and cellular thermal shift assays were used to predict and investigate the antiatherosclerotic mechanisms of CKN. CKN exhibited the greatest potency, with a 60.9% and 48.1% reduction in en face atherosclerotic lesions on the thoracic aorta and brachiocephalic trunk, reduced plasma lipid levels and decreased foam cell levels in the vascular plaque content in HHD-fed ApoE(−/−) mice. Moreover, CKN in the present study may exert its antiatherosclerotic effects through activated ABCA1 by promoting LXRα nuclear translocation and reducing the adverse effects of LXRα activation. CONCLUSIONS: Our results revealed that CKN prevented the formation of atherosclerosis in ApoE(−/−) mice by activating the LXRα pathway. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-023-00758-0. |
format | Online Article Text |
id | pubmed-10273626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102736262023-06-17 A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway Huang, Yan Ran, Xiaodong Liu, Hongmei Luo, Mingming Qin, Yiyu Yan, Jinqiong Li, Xiaohui Jia, Yi Chin Med Research BACKGROUND: We have previously demonstrated that ginsenoside compound K can attenuate the formation of atherosclerotic lesions. Therefore, ginsenoside compound K has potential for atherosclerosis therapy. How to improve the druggability and enhance the antiatherosclerotic activity of ginsenoside compound K are the core problems in the prevention and treatment of atherosclerosis. CKN is a ginsenoside compound K derivative that was previously reported to have excellent antiatherosclerotic activity in vitro, and we have applied for international patents for it. METHODS: Male C57BL/6 ApoE(−/−) mice were fed a high-fat and high-choline diet to induce atherosclerosis and were subjected to in vivo studies. In vitro, the CCK-8 method was applied to evaluate cytotoxicity in macrophages. Foam cells were utilized, and cellular lipid determination was performed for in vitro studies. The area of atherosclerotic plaque and fatty infiltration of the liver were measured by image analysis. Serum lipid and liver function were determined by a seralyzer. Immunofluorescence and western blot analysis were conducted to explore the alterations in the expression levels of lipid efflux-related proteins. Molecular docking, reporter gene experiments and cellular thermal shift assays were used to verify the interaction between CKN and LXRα. RESULTS: After confirming the therapeutic effects of CKN, molecular docking, reporter gene experiments and cellular thermal shift assays were used to predict and investigate the antiatherosclerotic mechanisms of CKN. CKN exhibited the greatest potency, with a 60.9% and 48.1% reduction in en face atherosclerotic lesions on the thoracic aorta and brachiocephalic trunk, reduced plasma lipid levels and decreased foam cell levels in the vascular plaque content in HHD-fed ApoE(−/−) mice. Moreover, CKN in the present study may exert its antiatherosclerotic effects through activated ABCA1 by promoting LXRα nuclear translocation and reducing the adverse effects of LXRα activation. CONCLUSIONS: Our results revealed that CKN prevented the formation of atherosclerosis in ApoE(−/−) mice by activating the LXRα pathway. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-023-00758-0. BioMed Central 2023-06-15 /pmc/articles/PMC10273626/ /pubmed/37322486 http://dx.doi.org/10.1186/s13020-023-00758-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Huang, Yan Ran, Xiaodong Liu, Hongmei Luo, Mingming Qin, Yiyu Yan, Jinqiong Li, Xiaohui Jia, Yi A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway |
title | A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway |
title_full | A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway |
title_fullStr | A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway |
title_full_unstemmed | A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway |
title_short | A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway |
title_sort | novel dammarane triterpenoid alleviates atherosclerosis by activating the lxrα pathway |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273626/ https://www.ncbi.nlm.nih.gov/pubmed/37322486 http://dx.doi.org/10.1186/s13020-023-00758-0 |
work_keys_str_mv | AT huangyan anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT ranxiaodong anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT liuhongmei anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT luomingming anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT qinyiyu anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT yanjinqiong anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT lixiaohui anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT jiayi anoveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT huangyan noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT ranxiaodong noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT liuhongmei noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT luomingming noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT qinyiyu noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT yanjinqiong noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT lixiaohui noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway AT jiayi noveldammaranetriterpenoidalleviatesatherosclerosisbyactivatingthelxrapathway |